WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05870-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Wenwen Guo und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Mutation, Myelodysplastic Syndromes, WT1 Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Wilms tumor 1 (WT1) gene mutations are infrequent in myelodysplastic syndrome (MDS), but MDS with WT1 mutations (WT1mut) is considered high risk for acute myeloid leukemia (AML) transformation. The influence of WT1 mutations in patients with MDS after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear. We performed a retrospective analysis of 136 MDS with excess blasts 2 (MDS-EB2) patients with available WT1 status who underwent their first allo-HSCT between 2017 and 2022 in our center. There were 20 (20/136, 15%) cases in the WT1mut group and 116 (116/136, 85%) cases in the WT1 wild-type (WT1wt) group. WT1mut patients had a higher 2-year cumulative incidence of relapse (CIR) than WT1wt cases (26.2% vs. 9.4%, p = 0.037) after allo-HSCT. Multivariate analysis of relapse showed that WT1 mutations (HR, 6.0; p = 0.002), TP53 mutations (HR, 4.2; p = 0.021), and ≥ 5% blasts in bone marrow (BM) at transplantation (HR, 6.6; p = 0.004) were independent risk factors for relapse. Patients were stratified into three groups according to the risk factors. Two-year CIR differed significantly in high-, intermediate-, and low-risk groups (31.8%, 11.6%, and 0%, respectively). Hence, WT1 mutations may be related to post-transplant relapse in patients with MDS-EB2, which warrants further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, 301600, China.
- Tianjin Institutes of Health Science, Tianjin, 301600, China. doctor_eljiang@163.com.
Zitieren
APA
Guo, W., Zhang, H., Wang, M., Zheng, Y., Cao, Y., Zhang, X., Zhai, W., Zhang, R., Yang, D., Wei, J., He, Y., Ma, Q., Xia, Y., Pang, A., Feng, S., Han, M., & Jiang, E. (2024). WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients. Annals of Hematology. https://doi.org/10.1007/s00277-024-05870-1
Vancouver
Guo W, Zhang H, Wang M, Zheng Y, Cao Y, Zhang X, et al. WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients. Annals of Hematology. 2024. doi:10.1007/s00277-024-05870-1
BibTeX
@article{Guo2024,
author = {Guo, Wenwen and Zhang, Haixiao and Wang, Mingyang and Zheng, Yawei and Cao, Yigeng and Zhang, Xiaoyu and Zhai, Weihua and Zhang, Rongli and Yang, Donglin and Wei, Jialin and He, Yi and Ma, Qiaoling and Xia, Yonghui and Pang, Aiming and Feng, Sizhou and Han, Mingzhe and Jiang, Erlie},
title = {WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05870-1}
}
EUVIMED